NCT06353971View on ClinicalTrials.gov

A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

March 18, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions
Chronic Inducible Urticaria
Interventions
DRUG

Briquilimab

Subcutaneous Injection

Trial Locations (5)

12203

Charité - University Clinic Berlin, Berlin

23538

University Clinic Schleswig-Holstein, Lübeck

35043

University of Marburg, Marburg

48149

University of Munster, Münster

01307

University Hospital Dresden, Dresden

Sponsors
All Listed Sponsors
lead

Jasper Therapeutics, Inc.

INDUSTRY